See more : CF Acquisition Corp. VI (CFVIU) Income Statement Analysis – Financial Results
Complete financial analysis of Genprex, Inc. (GNPX) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Genprex, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Meltronix, Inc. (MTNX) Income Statement Analysis – Financial Results
- Buligo Capital Ltd (BLGCF) Income Statement Analysis – Financial Results
- Runway Growth Finance Corp. 8.00% Notes due 2027 (RWAYZ) Income Statement Analysis – Financial Results
- Ching Feng Home Fashions Co.,Ltd (9935.TW) Income Statement Analysis – Financial Results
- Borregaard ASA (BRG.OL) Income Statement Analysis – Financial Results
Genprex, Inc. (GNPX)
About Genprex, Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its lead product candidate is REQORSA (GPX-001) to treat non-small cell lung cancer and small cell lung cancer. The company is also developing GPX-002, a preclinical stage gene therapy for diabetes. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 15.00K | 23.83M | 22.53K | 22.78K | 13.07K | 5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit | -15.00K | -23.83M | -22.53K | -22.78K | -13.07K | -5.89K | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 17.62M | 11.51M | 8.61M | 7.30M | 1.97M | 971.43K | 289.93K | 354.88K | 201.96K |
| General & Administrative | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 13.44M | 12.30M | 10.97M | 10.64M | 8.70M | 11.39M | 3.02M | 3.78M | 865.70K |
| Other Expenses | 0.00 | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 0.00 | 0.00 |
| Operating Expenses | 31.06M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Cost & Expenses | 31.08M | 23.83M | 19.60M | 17.96M | 10.68M | 12.36M | 3.31M | 4.13M | 1.07M |
| Interest Income | 215.11K | 90.10K | 5.13K | 18.81K | 27.91K | 29.18K | 80.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.98K | 1.89K | 0.00 | 0.00 |
| Depreciation & Amortization | 15.00K | 25.58K | 22.53K | 22.78K | 13.07K | 5.89K | 3.24K | 862.00 | 2.06K |
| EBITDA | -31.06M | -23.81M | -20.65M | -17.94M | -10.64M | -12.33M | -3.31M | -4.13M | -1.07M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -31.08M | -23.83M | -19.60M | -17.96M | -10.68M | -12.36M | -3.31M | -4.13M | -1.07M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 215.11K | 90.10K | 5.13K | 18.81K | 27.90K | -8.80K | -1.81K | 0.00 | 0.00 |
| Income Before Tax | -30.86M | -23.74M | -19.60M | -17.94M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 5.72M | -5.13K | -18.81K | -130.89K | 29.18K | 80.00 | 0.00 | 0.00 |
| Net Income | -30.86M | -29.46M | -19.59M | -17.92M | -10.65M | -12.37M | -3.31M | -4.13M | -1.07M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -22.58 | -24.59 | -16.64 | -20.18 | -26.64 | -35.97 | -11.55 | -15.30 | -23.25 |
| EPS Diluted | -22.56 | -24.58 | -16.64 | -20.18 | -26.59 | -35.94 | -11.53 | -15.26 | -22.93 |
| Weighted Avg Shares Out | 1.37M | 1.20M | 1.18M | 888.00K | 400.00K | 344.00K | 287.00K | 270.00K | 46.00K |
| Weighted Avg Shares Out (Dil) | 1.37M | 1.20M | 1.18M | 888.07K | 400.68K | 344.28K | 287.50K | 270.87K | 46.66K |
Genprex Receives Notice of Patent Grant for Korean Patent Claiming Reqorsa® Immunogene Therapy with PD-1 and PD-L1 Antibodies to Treat Cancers
Expands on the previously granted patents covering the use of REQORSA in combination with immune checkpoint inhibitors applicable to Genprex's Acclaim-2 and Acclaim-3 clinical trials AUSTIN, Texas , March 12, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX...
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® and on NPRL2 Gene Therapy Utilizing Non-Viral Oncoprex® Delivery System for the Treatment of Lung Cancers at the 2024 AACR Annual Meeting
Reqorsa® Immunogene Therapy May be a Potential Therapy for ALK-Positive Lung Cancer REQORSA has Anti-Tumor Mechanisms that Target and Disrupt the Metabolism of Cancer Cells NPRL2 Gene Therapy Induces Effective Anti-Tumor Immunity in Non-Small Cell Lung Cancer Humanized Mouse Model...
Genprex Expands Nonclinical Programs into New Therapeutic Indications with Research Collaborators
Reqorsa® Therapy May Be Potential Treatment for ALK-Positive Lung Cancer Three Collaborators Selected to Present Positive Nonclinical Data on Genprex Oncology Program at the 2024 American Association for Cancer Research (AACR) Annual Meeting AUSTIN, Texas , Feb. 7, 2024 /PRNewswire/ --...
Genprex to Present at Upcoming BIO CEO & Investor Conference
Presentation to Highlight Company's Gene Therapies for Cancer and Diabetes AUSTIN, Texas , Feb. 6, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer...
Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Expects to Complete Enrollment of Phase 2a Expansion Study by the end of 2024 Acclaim-1 Study Has FDA Fast Track Designation AUSTIN, Texas , Feb. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene...
Genprex Announces 1-for-40 Reverse Stock Split Effective February 2, 2024
AUSTIN, Texas , Jan. 31, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes, today announced that on February 2, 2024, the...
Genprex Provides Business Update and Outlook for 2024
Acclaim-1 Phase 2a and Acclaim-3 Phase 1 clinical studies opening for enrollment in January 2024 Poised for FDA guidance regarding diabetes gene therapy program in 2024 AUSTIN, Texas , Jan. 5, 2024 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company")...
Genprex to Present at BIO-Europe 2023 Conference
Presentation to be held on Tuesday, November 7, 2023 from 4:45 – 5:00 p.m. UTC AUSTIN, Texas , Nov. 1, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX ), a clinical-stage gene therapy company focused on developing...
Genprex to Host a Virtual Key Opinion Leader Event on "Bringing Gene Therapy to the Fight Against Lung Cancers"
Webinar to be held on Friday, October 27, 2023 from 12:30 pm - 1:45 pm Eastern Time AUSTIN, Texas , Oct. 20, 2023 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene therapy company focused on developing...
Genprex to Present Data on the Use of REQORSA® for the Treatment of Lung Cancers at 2023 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Acclaim-1 Phase 1 study had no Dose Limiting Toxicity, and results establish Phase 2 Recommended Dose as well as provide data showing efficacy of REQORSA® in combination with Tagrisso® Preclinical results show that REQORSA® in combination with a checkpoint inhibitor...
Source: https://incomestatements.info
Category: Stock Reports